TY - JOUR
T1 - High-risk stage II colon cancer after curative resection
AU - Sato, Harunobu
AU - Maeda, Koutarou
AU - Sugihara, Kenichi
AU - Mochizuki, Hidetaka
AU - Kotake, Kenjiro
AU - Teramoto, Tetsuo
AU - Kameoka, Shingo
AU - Saito, Yukio
AU - Takahashi, Keiichi
AU - Hirai, Takashi
AU - Ohue, Masayuki
AU - Shirouzu, Kazuo
AU - Sakai, Yoshiharu
AU - Watanabe, Toshiaki
AU - Hirata, Koichi
AU - Hatakeyama, Katsuyoshi
PY - 2011/7/1
Y1 - 2011/7/1
N2 - Objectives: This study was designed to clarify which attributes of stage II colon cancer are associated with tumor recurrence and survival after curative resection, and the effects of adjuvant chemotherapy (ACT). Methods: We retrospectively reviewed outcomes and clinicopathological characteristics of 1476 patients with stage II colon cancer who underwent curative resection. Results: Of 1476 patients, 204 (13.8%) developed recurrence. Macroscopic type, serum CA19-9 levels, venous invasion, emergency operation, and postoperative ileus were independently associated with overall recurrence. Carbohydrate antigen (CA)19-9 levels, the number of dissected lymph nodes (LN), sex, age, ACT, emergency operation, venous invasion, and macroscopic type were independently associated with poor prognosis. Prognosis was significantly better in patients who received ACT than in those who did not. Among patients with extensive venous invasion, those with fewer than 13 dissected LNs, male patients, and patients >50 years old, the prognosis was significantly better in patients who received ACT than in those who did not. Conclusions: ACT for stage II colon cancer is recommended to improve the prognosis of patients with extensive venous invasion, patients with fewer than 13 dissected LNs, patients >50 years old, and male patients, particularly patients with more than two of these risk factors.
AB - Objectives: This study was designed to clarify which attributes of stage II colon cancer are associated with tumor recurrence and survival after curative resection, and the effects of adjuvant chemotherapy (ACT). Methods: We retrospectively reviewed outcomes and clinicopathological characteristics of 1476 patients with stage II colon cancer who underwent curative resection. Results: Of 1476 patients, 204 (13.8%) developed recurrence. Macroscopic type, serum CA19-9 levels, venous invasion, emergency operation, and postoperative ileus were independently associated with overall recurrence. Carbohydrate antigen (CA)19-9 levels, the number of dissected lymph nodes (LN), sex, age, ACT, emergency operation, venous invasion, and macroscopic type were independently associated with poor prognosis. Prognosis was significantly better in patients who received ACT than in those who did not. Among patients with extensive venous invasion, those with fewer than 13 dissected LNs, male patients, and patients >50 years old, the prognosis was significantly better in patients who received ACT than in those who did not. Conclusions: ACT for stage II colon cancer is recommended to improve the prognosis of patients with extensive venous invasion, patients with fewer than 13 dissected LNs, patients >50 years old, and male patients, particularly patients with more than two of these risk factors.
KW - Adjuvant chemotherapy
KW - Colon carcinoma
KW - Curative resection
KW - Prognostic factors
UR - http://www.scopus.com/inward/record.url?scp=79958156608&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958156608&partnerID=8YFLogxK
U2 - 10.1002/jso.21914
DO - 10.1002/jso.21914
M3 - Article
C2 - 21416472
AN - SCOPUS:79958156608
SN - 0022-4790
VL - 104
SP - 45
EP - 52
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
IS - 1
ER -
